Farewell To The Slide
"There are about 17 million TB slide-based tests done in a year (in India). But conventional methods' sensitivity is 45-50 per cent; so you are missing half the number of TB patients."
BD also plans to introduce a molecular diagnostic platform, BD Max, in India for 20 different tests for illnesses such as TB, meningitis, sexually transmitted diseases as well as for many bacterial infections. Cervical cancer diagnosticsis also a focus area for BD in India.
The company's combined (medical technology,diagnostics and bioscience businesses) annual revenues from India are about $115 million, with diagnostics at $25 million.
(This story was published in Businessworld Issue Dated 04-06-2012)
Around The World